clinical trial · NCT05027906
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Prevention of Rejection in Kidney TransplantAT-1501
brief summary
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
started
Feb 18, 2022
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Jun 29, 2025
detailed description
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation. Up to 48 de novo kidney transplant recipients will receive AT-1501 in combination with rATG induction with corticosteroids (CS), and mycophenolate as maintenance therapy.
official title
A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol